D&A at other companies
Other financials
Where this comes from
Reported directly by Oric Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oric Pharmaceuticals, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oric Pharmaceuticals, Inc.'s D&A?
- Oric Pharmaceuticals, Inc. (ORIC) reported D&A of $270K in Q1 2026.
- How has Oric Pharmaceuticals, Inc.'s D&A changed year-over-year?
- Oric Pharmaceuticals, Inc.'s D&A decreased by 10.6% year-over-year, from $302K to $270K.
- What is the long-term trend for Oric Pharmaceuticals, Inc.'s D&A?
- Over 4 years (2021 to 2025), Oric Pharmaceuticals, Inc.'s D&A has grown at a 8.0% compound annual growth rate (CAGR), from $897K to $1.22M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.